The following information has been compiled from publicly available sources,
StratCom does not assume any responsibility for the accuracy or the authenticity
of the information and StratCom cannot be held liable for errors.
Dear Reader, thank you for your continued
support of this news service. As usual,
StratCom will take a break for the summer.
Monthly updates will resume in September.
Beckman
Coulter introduced the Access Inhibin A, an automated assay for the quantitative determination of
dimeric inhibin A levels in human serum and plasma. Inhibin A is used as an aid in the diagnosis
and monitoring of various reproductive hormonal disorders.
Bio-Rad
Laboratories launched two Epstein Barr Virus (EBV) kits for use on its BioPlex 2200 system. The IgG kit includes assays for EBV VCA, EBV
NA-1, and EBV EA-D, and the IgM kit includes assays for EBV VCA and heterophile
antibodies.
Cepheid
and Instrumentation Laboratory (IL) signed an
exclusive development and distribution to develop a line of tests for
hemostasis applications to be used on Cepheid’s GeneXpert System. IL will market these tests as a key complement
to its panel of automated hemostasis diagnostic assays. The first tests will be the Xpert HemosIL Factor II and Factor V tests.
Diazyme
Laboratories received FDA clearance to market its
Direct Enzymatic Hemoglobin A1c (HbA1c) Assay Kit for the quantitative determination of HbA1c in
human whole blood samples. The HbA1c
test uses two ready-to-use liquid stable reagents. Since it does not require a
separate measurement of total hemoglobin content in the samples, the assay only
needs a single channel to perform the test on chemistry analyzers in comparison
with some immunoassays that require a separated measurement of total hemoglobin
and need two channels for the test on chemistry analyzers.
Polymedco introduced its POC BTA
stat test for the detection of recurrent bladder cancer. This method uses
monoclonal antibodies to detect the presence of bladder tumor associated antigen
in urine. It is a single-step, rapid immunochromatographic assay for bladder
tumor-associated antigen in voided urine.
SmartGene entered into a strategic collaboration with LabCorp. LabCorp will use
SmartGene's advanced technology and integrated Web-based services to support
more rapid and precise identification of bacterial
and fungal pathogens.
![[Page Banner Image]](images/hprods.gif){kind=small}
![[HRule Image]](images/div.jpg){kind=small}
